enVVeno Medical Corporation Common Stock (NVNO)

About NVNO

enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an ope…

Sector

Health Care

Industry

Medical/Dental Instruments

Employees

33

Website

envveno.com/

Fundamentals

1-day range

$10.7$10.75

Market cap

$6.93M

P/E (trailing)

—

P/E (forward)

-1.73

EPS (trailing)

$-25.19

Dividend yield

—

Beta

1.25

Avg. volume

15.8K

Dividend pay date

November 30, 2020

Forecasts

1 analyst ratings

enVVeno Medical Corporation Common Stock Competitors

Chosen by industry and closest market cap.

• NVNO

  enVVeno Medical Corporation Common Stock

  $10.67

  ▼ 5.12%
  Market cap $6.93MP/E —
  $8.67$36.05
• XAIR

  Beyond Air Inc. Common Stock

  $4.58

  ▼ 19.65%
  Market cap $4.93MP/E —
  $4.37$95.6
• INBS

  Intelligent Bio Solutions Inc. Common Stock

  $2.36

  ▲ 3.96%
  Market cap $4.76MP/E —
  $1.52$24.9
• VVOS

  Vivos Therapeutics Inc. Common Stock

  $0.2245

  ▼ 12.98%
  Market cap $4.47MP/E —
  $0.24$4.93
• CODX

  Co-Diagnostics Inc. Common Stock

  $1.2

  ▼ 4.76%
  Market cap $9.91MP/E —
  $0.9396$46.5
• SINT

  SiNtx Technologies Inc. Common Stock

  $1.51

  ▼ 1.31%
  Market cap $10.36MP/E —
  $1.4$6.78
• MODD

  Modular Medical Inc. Common Stock

  $3.3

  ▼ 8.73%
  Market cap $10.99MP/E —

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• enVVeno Medical Files Prospectus To Offer And Sell Securities For Up To $100M
  Benzinga · 8/21/2026
• enVVeno Announces Publication Of Peer-Reviewed Health Economics Study Supporting Venous Valve Therapy; Findings May Support Future Coverage And Reimbursement Decisions
  Benzinga · 8/4/2026
• enVVeno Medical Q2 EPS $(5.37) Up From $(11.55) YoY
  Benzinga · 7/31/2026

• Francis Duhay · June 11, 2026 · Sale

  140 @ $10.31
• Francis Duhay · March 12, 2026 · Sale

  140 @ $11.52

Institutional Ownership

March 31, 2026

Total shares held

93.0K

Total value held

$942.5K

Institutional holders

14